Citations

Clear

5 citation(s) found for "Gray, Elizabeth".

The PRO ‐ AGE Tool and Its Association With Post Discharge Outcomes in Older Adults Admitted From the Emergency Department
Cohen, Inessa , Morinaga, Christian Valle , Han, Ling, Araujo, Katy, Avelino‐Silva, Thiago Junqueira , Bianco, Luann, Capelli, Sandra, Cruz, Daniel S. , Fishman, Ivy L., Gipson, Katrina, Gray, Elizabeth , Hung, William W. , Kang, Raymond , Lockhart, Mechelle, Ohuabunwa, Ugochi , Ottilie‐Kovelman, Sierra, Platts‐Mills, Timothy F. , Sandoval, Jacqueline , Sifnugel, Natalia, Taylor, Zachary , Tomasino, Debra F. , Vaughan, Camille P. , Hwang, Ula , Carpenter, Christopher R , Cruz, Daniel S , Ohuabunwa, Ugochi , Sandoval, Jacqueline , Vaughan, Camille P , Aliberti, Márlon J R , Hwang, Ula , Avelino-Silva, Thiago Junqueira , Curiati, Pedro Kallas , Gandhi, Tanish , Brandt, Cynthia , Carpenter, Christopher R. , Dresden, Scott M. , Hastings, Susan N. , Meeker, Daniella , Taylor, Zachary

Mayo Clinic

Journal of the American Geriatrics Society | January 22, 2025 | Volume: 73 | Issue: 5 | Pages: 1419-1428

10.1111/jgs.19374 | PMID 39843218 Get It

ABSTRACT Background Existing risk scores assessing geriatric vulnerability in the emergency department (ED) have shown limited predictive power, especially in diverse populations. We investigated the relationship of a quick and easy‐to‐administer geriatric vulnerability scoring system with functional decline and mortality in older patients admitted to multiple hospitals through the ED in the United States (US) and Brazil (BR). Method Federated, international, multicenter observational study of hospitalized ED patients aged ≥ 65 from US and BR. The six criteria from the PRO‐AGE score (Physical impairment, Recent hospitalization, Older age [≥ 90], Acute mental alteration, Getting thinner, and Exhaustion; 0–8; higher scores = greater vulnerability) were assessed on admission. We used proportional hazards models to investigate the relationships between PRO‐AGE score groups and 90‐day mortality and functional decline, defined as new dependence in activities of daily living (ADL) and instrumental ADL (IADL), after adjusting for age, sex, race and ethnicity, education, Charlson comorbidity score, and study site. Death was considered a competing event for the functional decline outcome. Results A total of 1390 patients were included (US = 560; Brazil = 830). The 90‐day risk of death was higher for the upper compared with the lower (reference) PRO‐AGE group in both cohorts (US: HR = 11.76; 95% confidence interval [CI] = 2.56–54.04; BR: HR = 12.29; 95% CI = 3.54–42.59), whereas the risk of new 90‐day ADL disability was higher for upper (HR = 2.08; 95% CI = 1.21–3.56) and middle groups (HR = 2.10; 95% CI = 1.35–3.27) in the US but only the upper group in BR (HR = 1.70; 95% CI = 1.02–2.85). Conclusion A higher PRO‐AGE score was associated with mortality and functional decline in older ED patients admitted to hospitals in the US and BR, demonstrating its generalizability as a geriatric vulnerability risk score.
Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)
Mehrotra, Shailly , Gray, Elizabeth, Wu, Kehua, Barry, William T., Hudis, Clifford A. , Lyss, Alan P., Toppmeyer, Deborah , Moreno‐Aspitia, Alvaro , Lad, Thomas E. , Velasco, Mario R. , Overmoyer, Beth , Ratain, Mark J. , Sharma, Manish R. , Gray, Elizabeth, Winer, Eric P. , Rugo, Hope S. , Gobburu, Jogarao , Sharma, Manish R.

Mayo Clinic

The Journal of Clinical Pharmacology | December 5, 2019 | Volume: 60 | Issue: 4 | Pages: 444-452

10.1002/jcph.1559 | PMID 31802506 Get It

AbstractChemotherapy‐induced peripheral neuropathy (henceforth, neuropathy) is often dose limiting and is generally managed by empirical dose modifications. We aimed to (1) identify an early time point that is predictive of future neuropathy using a patient‐reported outcome and (2) propose a dose‐adjustment algorithm based on simulated data to manage neuropathy. In previous work, a dose‐neuropathy model was developed using dosing and patient‐reported outcome data from Cancer and Leukemia Group B 40502 (Alliance), a randomized phase III trial of paclitaxel, nanoparticle albumin–bound paclitaxel or ixabepilone as first‐line chemotherapy for locally recurrent or metastatic breast cancer. In the current work, an early time point that is predictive of the future severity of neuropathy was identified based on predictive accuracy of the model. Using the early data and model parameters, simulations were conducted to propose a dose‐adjustment algorithm for the prospective management of neuropathy in individual patients. The end of the first 3 cycles (12 weeks) was identified as the early time point based on a predictive accuracy of 75% for the neuropathy score after 6 cycles. For paclitaxel, nanoparticle albumin–bound paclitaxel, and ixabepilone, simulations with the proposed dose‐adjustment algorithm resulted in 61%, 48%, and 35% fewer patients, respectively, with neuropathy score ≥8 after 6 cycles compared to no dose adjustment. We conclude that early patient‐reported outcome data on neuropathy can be used to guide dose adjustments in individual patients that reduce the severity of future neuropathy. Prospective validation of this approach should be undertaken in future studies.
A model-based approach to dose optimization of neurotoxic chemotherapy for metastatic breast cancer (MBC).
Gray, Elizabeth, Mehrotra, Shailly , Wu, Kehua, Barry, William T., Hudis, Clifford A. , Lyss, Alan P., Toppmeyer, Deborah , Moreno‐Aspitia, Alvaro , Ratain, Mark J. , Sharma, Manish R. , Gray, Elizabeth, Winer, Eric P. , Rugo, Hope S. , Gobburu, Jogarao

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 1041-1041

10.1200/jco.2015.33.15_suppl.1041 Get It

Reactivation of Chagas disease among heart transplant recipients in the United States, 2012‐2016
Gray, Elizabeth B. , Hoz, Ricardo M. La , Green, Jaime S. , Vikram, Holenarasipur R. , Benedict, Theresa, Rivera, Hilda N., Montgomery, Susan P. , Vikram, Holenarasipur R. , La Hoz, Ricardo M

Mayo Clinic

Transplant Infectious Disease | September 11, 2018 | Volume: 20 | Issue: 6 | Pages: No page available

10.1111/tid.12996 | PMID 30204269 Get It

AbstractBackgroundHeart transplantation has been shown to be a safe and effective intervention for progressive cardiomyopathy from chronic Chagas disease. However, in the presence of the immunosuppression required for heart transplantation, the likelihood of Chagas disease reactivation is significant. Reactivation may cause myocarditis resulting in allograft dysfunction and the rapid onset of congestive heart failure. Reactivation rates have been well documented in Latin America; however, there is a paucity of data regarding the risk in non‐endemic countries.MethodsWe present our experience with 31 patients with chronic Chagas disease who underwent orthotopic heart transplantation in the United States from 2012 to 2016. Patients were monitored following a standard schedule.ResultsOf the 31 patients, 19 (61%) developed evidence of reactivation. Among the 19 patients, a majority (95%) were identified by laboratory monitoring using polymerase chain reaction testing. One patient was identified after the onset of clinical symptoms of reactivation. All subjects with evidence of reactivation were alive at follow‐up (median: 60 weeks).ConclusionsTransplant programs in the United States are encouraged to implement a monitoring program for heart transplant recipients with Chagas disease. Our experience using a preemptive approach of monitoring for Chagas disease reactivation was effective at identifying reactivation before symptoms developed.
Resampling the N9741 Trial to Compare Tumor Dynamic Versus Conventional End Points in Randomized Phase II Trials
Gray, Elizabeth, Goldberg, Richard M. , Karrison, Theodore , Sharma, Manish R. , Karrison, Theodore G, Sharma, Manish R. , Sargent, Daniel J.

Mayo Clinic

Journal of Clinical Oncology | October 28, 2014 | Volume: 33 | Issue: 1 | Pages: 36-41

10.1200/jco.2014.57.2826 | PMID 25349295 Get It

Purpose The optimal end point for randomized phase II trials of anticancer therapies remains controversial. We simulated phase II trials by resampling patients from N9741, a randomized phase III trial of chemotherapy regimens for metastatic colorectal cancer, and compared the power of various end points to detect the superior therapy (FOLFOX [infusional fluorouracil, leucovorin, and oxaliplatin] had longer overall survival than both IROX [irinotecan plus oxaliplatin] and IFL [irinotecan and bolus fluorouracil plus leucovorin]). Methods Tumor measurements and progression-free survival (PFS) data were obtained for 1,471 patients; 1,002 had consistently measured tumors and were resampled (5,000 replicates) to simulate two-arm, randomized phase II trials with α = 0.10 (one sided) and 20 to 80 patients per arm. End points included log ratio of tumor size at 6, 12, and 18 weeks relative to baseline; time to tumor growth (TTG), estimated using a nonlinear mixed-effects model; and PFS. Arms were compared using rank sum tests for log ratio and TTG and a log-rank test for PFS. Results For FOLFOX versus IFL, TTG and PFS had similar power, with both exceeding the power of log ratio at 18 weeks; for FOLFOX versus IROX, TTG and log ratio at 18 weeks had similar power, with both exceeding the power of PFS. The best end points exhibited > 80% power with 60 to 80 patients per arm. Conclusion TTG is a powerful end point for randomized phase II trials of cytotoxic therapies in metastatic colorectal cancer; it was either comparable or superior to PFS and log ratio at 18 weeks. Additional studies will be needed to clarify the potential of TTG as a phase II end point.